Monte Rosa Therapeutics Inc

NASDAQ GLUE

Data sourced from

and

Download Data

Monte Rosa Therapeutics Inc Inventory Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2024

Monte Rosa Therapeutics Inc Inventory Turnover Ratio is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The inventory turnover ratio measures the efficiency of a company's inventory management by assessing how quickly it sells and replaces its inventory. It is calculated by dividing the cost of revenue by the average inventory value. This ratio indicates the number of times the company's inventory is sold and replaced within a specific period. A higher turnover ratio suggests efficient inventory management, while a lower ratio may indicate slow sales or excess inventory.

NASDAQ: GLUE

Monte Rosa Therapeutics Inc

CEO	Dr. Markus Warmuth M.D.
IPO Date	June 24, 2021
Location	United States
Headquarters	645 Summer Street, Boston, MA, United States, 02210
Employees	130
Sector	Healthcare
Industry	Biotechnology

Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Key trends